论文部分内容阅读
行业一周动态医保药品招标或告别“低价至上”近日,多家媒体报道,有“普药之王”之称的四川蜀中制药由于涉嫌虚假投料已被停产整顿。该公司是业内较大的普药生产企业,同时也是多种医保品种的中标企业。如果造假行为属实,必然会带来医药行业的地震,也会对政府相关部门的现有药品招标模式产生影响。
Industry Weekly Medicare bidding or bid farewell “low price top ” Recently, many media reports, “drug of the king ” said Sichuan Shu in the pharmaceutical because of suspected false feedstock has been suspended for rectification. The company is the industry’s largest general-purpose drug manufacturers, but also a variety of successful varieties of medical insurance companies. If the fraud is true, it will inevitably bring about the earthquake in the pharmaceutical industry and will also affect the existing drug bidding model of relevant government departments.